Dihon Pharmaceutical Sale To Bayer Likely Scuttles IPO Plans
This article was originally published in PharmAsia News
Executive Summary
Dihon Pharmaceutical’s recent sale to Bayer HealthCare has likely scuttled plans for an initial public offering, according to private equity fund Jiangsu Jinmao Venture Investment Management, which held 3.5% of Dihon prior to the sale to Bayer.